The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
08 2019
Historique:
received: 25 07 2018
accepted: 22 01 2019
pubmed: 26 2 2019
medline: 4 11 2020
entrez: 26 2 2019
Statut: ppublish

Résumé

High-quality management of prostate cancer is needed in the fields of clinics, research, and education. The objective of this project was to develop the concept of "European Prostate Cancer Centres of Excellence" (EPCCE), with the specific aim of identifying European centres characterised by high-quality cancer care, research, and education. A task force of experts aimed at identifying the general criteria to define the EPCCE. Discussion took place in conference calls and by e-mail from March 2017 to November 2017, and the final consensus meeting named "European Association of Urology (EAU) Prostate Cancer Centre Consensus Meeting" was held in Barcelona on November 16, 2017. The required criteria were grouped into three main steps: (1) clinics, (2) research, and (3) education. A quality control approach for the three steps was defined. The definition of EPCCE consisted of the following steps: (1) clinical step-five items were identified and classified as core team, associated services, multidisciplinary approach, diagnostic pathway, and therapeutic pathway; (2) research step-internal monitoring of outcomes was required; clinical data had to be collected through a prespecified database, clinical outcomes had to be periodically assessed, and prospective trials had to be conducted; (3) educational step-it consists of structured fellowship programmes of 1yr, including 6mo of research and 6mo of clinics; and (4) quality assurance and quality control procedures, related to the quality assessment of the previous three steps. A limitation of this project was that the definition of standards and items was mainly based on a consensus among experts rather than being an evidence-based process. The EAU Prostate Cancer Centre Consensus Meeting defined the criteria for the identification of the EPCCE in the fields of clinics, research, and education. The inclusion of a quality control approach represents the novelty that supports the excellence of these centres. A task force of experts defined the criteria for the identification of European Prostate Cancer Centres of Excellence, in order to certify the high-quality centres for prostate cancer management.

Sections du résumé

BACKGROUND
High-quality management of prostate cancer is needed in the fields of clinics, research, and education.
OBJECTIVE
The objective of this project was to develop the concept of "European Prostate Cancer Centres of Excellence" (EPCCE), with the specific aim of identifying European centres characterised by high-quality cancer care, research, and education.
DESIGN, SETTING, AND PARTICIPANTS
A task force of experts aimed at identifying the general criteria to define the EPCCE. Discussion took place in conference calls and by e-mail from March 2017 to November 2017, and the final consensus meeting named "European Association of Urology (EAU) Prostate Cancer Centre Consensus Meeting" was held in Barcelona on November 16, 2017.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
The required criteria were grouped into three main steps: (1) clinics, (2) research, and (3) education. A quality control approach for the three steps was defined.
RESULTS AND LIMITATIONS
The definition of EPCCE consisted of the following steps: (1) clinical step-five items were identified and classified as core team, associated services, multidisciplinary approach, diagnostic pathway, and therapeutic pathway; (2) research step-internal monitoring of outcomes was required; clinical data had to be collected through a prespecified database, clinical outcomes had to be periodically assessed, and prospective trials had to be conducted; (3) educational step-it consists of structured fellowship programmes of 1yr, including 6mo of research and 6mo of clinics; and (4) quality assurance and quality control procedures, related to the quality assessment of the previous three steps. A limitation of this project was that the definition of standards and items was mainly based on a consensus among experts rather than being an evidence-based process.
CONCLUSIONS
The EAU Prostate Cancer Centre Consensus Meeting defined the criteria for the identification of the EPCCE in the fields of clinics, research, and education. The inclusion of a quality control approach represents the novelty that supports the excellence of these centres.
PATIENT SUMMARY
A task force of experts defined the criteria for the identification of European Prostate Cancer Centres of Excellence, in order to certify the high-quality centres for prostate cancer management.

Identifiants

pubmed: 30799188
pii: S0302-2838(19)30077-6
doi: 10.1016/j.eururo.2019.01.033
pii:
doi:

Types de publication

Consensus Development Conference Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-186

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Manfred Wirth (M)

European Association of Urology (EAU), Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. Electronic address: Manfred.Wirth@uniklinikum-dresden.de.

Nicola Fossati (N)

European Association of Urology (EAU), Division of Oncology / Unit of Urology; IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: fossati.nicola@hsr.it.

Peter Albers (P)

European Association of Urology (EAU), Department of Urology, University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Düsseldorf, Germany. Electronic address: Peter.Albers@med.uni-duesseldorf.de.

Chris Bangma (C)

European Association of Urology (EAU), Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands. Electronic address: c.h.bangma@erasmusmc.nl.

Maurizio Brausi (M)

EAU Section of Oncological Urology (ESOU)Department of Urology, B. Ramazzini Hospital, Carpi-Modena, Italy. Electronic address: m.brausi@ausl.mo.it.

Eva Comperat (E)

Service d'anatomie et cytologie pathologiques, hôpital Tenon, HUEP, Sorbonne université, Paris, France. Electronic address: eva.comperat@aphp.fr.

Sara Faithfull (S)

European Association of Urology Nurses (EAUN), School of Health Sciences, Faculty of Health & Medical Sciences, Duke of Kent Building, University of Surrey,Surrey, UK. Electronic address: s.faithfull@surrey.ac.uk.

Silke Gillessen (S)

European Organisation for Research and Treatment of Cancer (EORTC), Manchester Cancer Research Centre, Manchester, UK. Electronic address: silke.gillessen@kssg.ch.

Barbara Alicja Jereczek-Fossa (BA)

European Society for Radiotherapy and Oncology (ESTRO), Department of Oncology and Hemato-oncology, University of Milan, Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: barbara.jereczek@ieo.it.

Ken Mastris (K)

Europa Uomo (EUomo). Electronic address: ken.mastris@btinternet.com.

Nicolas Mottet (N)

European Association of Urology (EAU), Department of Urology, University Hospital, St. Etienne, France. Electronic address: nicolas.mottet@chu-st-etienne.fr.

Stefan C Müller (SC)

European Board of Urology (EBU), Arnhem, The Netherlands. Electronic address: stefan.mueller@ukb.uni-bonn.de.

Bradley Pieters (B)

European Society for Radiotherapy and Oncology (ESTRO), Amsterdam University Medical Centers / University of Amsterdam, Amsterdam, The Netherlands. Electronic address: b.r.pieters@amc.uva.nl.

Maria J Ribal (MJ)

European Urological Scholarship Programme (EUSP), Uro-Oncology Unit. Hospital Clínic. University of Barcelona, Spain. Electronic address: mjribal@clinic.cat.

Vijay Sangar (V)

European Association of Urology (EAU), The Christie NHS Foundation Trust & Manchester University Hospital NHS Foundation Trust, Manchester, UK. Electronic address: vpsangar@gmail.com.

Ivo G Schoots (IG)

European Society of Uro Radiology (ESUR), Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: i.schoots@erasmusmc.nl.

Vitaly Smelov (V)

Prevention and Implementation Group, Section of Early Detection and Prevention, International Agency for Research on Cancer (IARC), World Health Organization (WHO). Electronic address: smelovV@iarc.fr.

Luzia Travado (L)

International Psycho-Oncology Society (IPOS), Psycho-oncology, Champalimaud Clinical and Research Center, Champalimaud Foundation, Lisbon, Portugal. Electronic address: luzia.travado@fundacaochampalimaud.pt.

Riccardo Valdagni (R)

European School of Oncology (ESO), University of Milan, Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Oncology, Milano, Italy. Electronic address: Riccardo.Valdagni@istitutotumori.mi.it.

Simone Wesselmann (S)

German Cancer Society (DKG), Berlin, Germany. Electronic address: wesselmann@krebsgesellschaft.de.

Thomas Wiegel (T)

European Society for Radiotherapy and Oncology (ESTRO) Milan, Italy. Electronic address: Thomas.Wiegel@uniklinik-ulm.de.

Hendrik van Poppel (H)

European Association of Urology (EAU), Dept Urology, University Hospital KU Leuven, Belgium. Electronic address: hendrik.vanpoppel@uzleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH